Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Indivior Pharmaceuticals (INDV) Long-Term Deferred Tax (2021 - 2026)

Indivior Pharmaceuticals has reported Long-Term Deferred Tax over the past 6 years, most recently at $296.0 million for Q1 2026.

  • For Q1 2026, Long-Term Deferred Tax rose 6.09% year-over-year to $296.0 million; the TTM value through Mar 2026 reached $296.0 million, up 6.09%, while the annual FY2025 figure was $323.0 million, 16.61% up from the prior year.
  • Long-Term Deferred Tax for Q1 2026 was $296.0 million at Indivior Pharmaceuticals, down from $323.0 million in the prior quarter.
  • Over five years, Long-Term Deferred Tax peaked at $323.0 million in Q4 2025 and troughed at $210.0 million in Q2 2023.
  • A 5-year average of $273.2 million and a median of $279.0 million in 2025 define the central range for Long-Term Deferred Tax.
  • Biggest five-year swings in Long-Term Deferred Tax: surged 108.57% in 2022 and later dropped 6.9% in 2025.
  • Year by year, Long-Term Deferred Tax stood at $219.0 million in 2022, then soared by 30.59% to $286.0 million in 2023, then decreased by 3.15% to $277.0 million in 2024, then increased by 16.61% to $323.0 million in 2025, then fell by 8.36% to $296.0 million in 2026.
  • Business Quant data shows Long-Term Deferred Tax for INDV at $296.0 million in Q1 2026, $323.0 million in Q4 2025, and $285.0 million in Q3 2025.